Galmed Pharmaceuticals Ltd. (GLMD): Price and Financial Metrics

Galmed Pharmaceuticals Ltd. (GLMD): $0.65

-0.02 (-2.98%)

POWR Rating

Component Grades













Add GLMD to Watchlist
Sign Up

Industry: Biotech



in industry

GLMD Stock Price Chart Interactive Chart >

Price chart for GLMD

GLMD Price/Volume Stats

Current price $0.65 52-week high $1.84
Prev. close $0.67 52-week low $0.29
Day low $0.65 Volume 52,600
Day high $0.72 Avg. volume 168,944
50-day MA $0.50 Dividend yield N/A
200-day MA $0.56 Market Cap 16.33M

Galmed Pharmaceuticals Ltd. (GLMD) Company Bio

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company was founded in 2000 and is based in Tel Aviv, Israel.

GLMD Latest News Stream

Event/Time News Detail
Loading, please wait...

GLMD Latest Social Stream

Loading social stream, please wait...

View Full GLMD Social Stream

Latest GLMD News From Around the Web

Below are the latest news stories about GALMED PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate GLMD as an investment opportunity.

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | January 6, 2023

Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday''s Mid-Day Session

Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS ) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea. Crown ElectroKinetics Corp. (NASDAQ: CRKN ) climbed 162% to $0.4909 after the company announced it acquired Amerigen 7. Cryptyde, Inc. (NASDAQ: TYDE ) gained 108% to $0.4022. Geron Corporation (NASDAQ: GERN ) shares jumped 53.3% to $3.6800 after the company announced top-line results from the IMerge Phase 3 trial of imetelstat in lower risk MDS. The trial met the primary 8-week transfusion independence (TI) endpoint and key secondary 24-week TI endpoint. Shift Technologies, Inc. (NASDAQ: SFT ) rose 49% to $0.2350. Neptune Wellness Solutions Inc. (NASDAQ: NEPT ) jumped 42.4% to $0...

Benzinga | January 4, 2023

Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol

Histological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according to NASH CRN, in 61% of subjects by ranked assessment with a highly statistically significant (p<0.0001) reduction in fibrosis score demonstrated using AI-assisted, digital pathology reading Highly statistically significant (p<0.0001) reduction in liver stiffness by Fibroscan Highly statistically significant (p<0.0001) reduction in biochemical markers of liver injury ALT and AST Highly statistically significant reductions in major fibrosis biomarkers: FIB-4 (p<0.0001), Pro-C3 (p<0.0001) and ELF (p= 0.0038) at week 24 Galmed is submitting all data to the FDA to initiate discussions on incorporating more sensitive histology reading methodologies as primary endpoints in NASH clinical studies and is...

Benzinga | January 4, 2023

Galmed Pharmaceuticals gets an extension from Nasdaq to regain compliance

Galmed Pharmaceuticals (GLMD) received a letter from The Nasdaq, notifying the company that it is eligible for an additional 180 calendar day period, or until June 12, 2023.This…

Seeking Alpha | December 15, 2022

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq''s Minimum Bid Price Requirement

TEL AVIV, Israel, Dec. 14, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a biopharmaceutical company focused on the development of Aramchol and Amilo-5MER, announced today that on December 13, 2022, it received a letter from The Nasdaq Stock…

PR Newswire | December 14, 2022

Read More 'GLMD' Stories Here

GLMD Price Returns

1-mo 37.60%
3-mo 62.62%
6-mo 29.46%
1-year -53.24%
3-year -88.81%
5-year -94.06%
YTD 30.00%
2022 -72.53%
2021 -41.48%
2020 -46.19%
2019 -15.37%
2018 -25.36%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.788 seconds.